Alkermes Plc is a global biopharmaceutical company, which engages in the business of developing, manufacturing, and commercializing medicines designed to address unmet medical needs of patients in major therapeutic areas such as alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurological disorders and cancer. Its proprietary products include ARISTADA, ARISTADA INITIO, LYBALVI, and VIVITROL. The company was founded in 1987 and is headquartered in Dublin, Ireland. |  |
|
|
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Hopkinson Craig C. | Officer | Feb 13 '25 | Proposed Sale | 35.53 | 144,419 | 5,130,694 | | Feb 13 04:36 PM | Hopkinson Craig C. | Officer | Feb 12 '25 | Proposed Sale | 32.78 | 204,921 | 6,718,276 | | Feb 12 04:19 PM | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Jan 30 '25 | Option Exercise | 22.22 | 97,632 | 2,169,137 | 145,208 | Jan 31 08:42 PM | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Jan 30 '25 | Sale | 32.05 | 100,918 | 3,234,382 | 44,290 | Jan 31 08:42 PM | Hopkinson Craig C. | Officer | Jan 30 '25 | Proposed Sale | 32.05 | 100,918 | 3,234,380 | | Jan 30 05:12 PM | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Dec 09 '24 | Option Exercise | 22.70 | 48,997 | 1,112,259 | 108,727 | Dec 09 08:53 PM | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Dec 09 '24 | Sale | 32.07 | 61,151 | 1,961,406 | 47,576 | Dec 09 08:53 PM | LAURENCIN CATO T | Director | Dec 09 '24 | Option Exercise | 22.52 | 2,691 | 60,601 | 25,704 | Dec 09 08:51 PM | LAURENCIN CATO T | Director | Dec 09 '24 | Sale | 31.85 | 2,691 | 85,708 | 23,013 | Dec 09 08:51 PM | LAURENCIN CATO T | Director | Dec 09 '24 | Proposed Sale | 31.85 | 2,691 | 85,708 | | Dec 09 05:27 PM | Hopkinson Craig C. | Officer | Dec 09 '24 | Proposed Sale | 32.07 | 61,151 | 1,961,404 | | Dec 09 05:24 PM | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Dec 05 '24 | Sale | 31.50 | 9,221 | 290,462 | 59,730 | Dec 05 06:01 PM | Hopkinson Craig C. | Officer | Dec 05 '24 | Proposed Sale | 31.50 | 9,221 | 290,462 | | Dec 05 04:12 PM | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Dec 04 '24 | Sale | 30.77 | 14,349 | 441,550 | 68,951 | Dec 04 04:52 PM | Hopkinson Craig C. | Officer | Dec 04 '24 | Proposed Sale | 30.77 | 14,349 | 441,550 | | Dec 04 04:19 PM | Nichols Christian Todd | Officer | Nov 27 '24 | Proposed Sale | 29.15 | 5,208 | 151,813 | | Nov 27 04:33 PM | Nichols Christian Todd | SVP, Chief Commercial Officer | Nov 27 '24 | Sale | 29.15 | 5,208 | 151,813 | 60,703 | Nov 27 04:22 PM | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Nov 11 '24 | Option Exercise | 20.03 | 43,058 | 862,452 | 142,296 | Nov 12 04:48 PM | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Nov 11 '24 | Sale | 30.08 | 58,996 | 1,774,576 | 83,300 | Nov 12 04:48 PM | Hopkinson Craig C. | Officer | Nov 11 '24 | Proposed Sale | 30.08 | 58,996 | 1,774,578 | | Nov 12 04:15 PM | Hopkinson Craig C. | EVP R&D, Chief Medical Officer | Nov 06 '24 | Sale | 29.53 | 10,471 | 309,169 | 99,238 | Nov 06 07:47 PM | Hopkinson Craig C. | Officer | Nov 06 '24 | Proposed Sale | 29.53 | 10,471 | 309,169 | | Nov 06 04:33 PM | Nichols Christian Todd | SVP, Chief Commercial Officer | Mar 18 '24 | Sale | 28.10 | 10,417 | 292,740 | 65,911 | Mar 18 04:02 PM | Parisi Samuel Joseph | VP, Finance (Interim PAO) | Feb 27 '24 | Sale | 29.65 | 2,559 | 75,874 | 7,717 | Feb 27 04:09 PM | LAURENCIN CATO T | Director | Feb 15 '24 | Option Exercise | 22.52 | 2,690 | 60,579 | 17,859 | Feb 16 04:01 PM | LAURENCIN CATO T | Director | Feb 15 '24 | Sale | 31.85 | 2,690 | 85,676 | 15,169 | Feb 16 04:01 PM |
|